Impact of benralizumab treatment on asthma

Impact of benralizumab treatment on circulating dendritic cells in patients with eosinophilic asthma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2018-000578-31-DE

Enrollment

Registered

2018-04-05

Start date

2018-07-05

Completion date

Unknown

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic Asthma

Interventions

Trade Name: Fasenra Product Name: Fasenra Pharmaceutical Form:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Asthma Blood eosinophils > 300 cells / µl blood ICS-LABA-Therapy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5

Exclusion criteria

Exclusion criteria: Current Smoking Immunosuppression (except ICS) Pregnancy Other chronic inflammatory diseases

Design outcomes

Primary

Measure	Time frame
Secondary Objective: Impact of benralizumab treatment on circulating T cells in patients with eosinophilic asthma;Primary end point(s): Blood dendritic cell characteristics;Timepoint(s) of evaluation of this end point: week 0, 12, 24 (time points 1,4,5);Main Objective: Impact of benralizumab treatment on circulating dendritic cells in patients with eosinophilic asthma	—

Secondary

Measure	Time frame
Secondary end point(s): Investigation of the impact of benralizumab treatment on the concentration and phenotype of circulating T cells in patients with asthma;Timepoint(s) of evaluation of this end point: week 0, 12, 24 (time points 1,4,5)	—

Countries

Germany

Contacts

Public ContactClinical Trials Information

University Medicine Rostock

00493814947461

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026